---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-176312"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2024-07-08T23:59:59+00:00"
generated_at: "2026-05-31T23:07:04.101691+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sanofi expands KT-474 Phase 2 trials in HS and AD after positive interim data review

## Summary
- Sanofi to expand ongoing Phase 2 trials for KT-474 in hidradenitis suppurativa and atopic dermatitis.
- Expansion follows interim safety and efficacy review by an Independent Data Review Committee.
- Move intended to accelerate timelines and progress toward pivotal registrational studies.
- Kymera CEO Nello Mainolfi cites potential to address large unmet needs with high market potential.

## SEC filing metadata
- accession: 0001193125-24-176312
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2024-07-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312524176312/0001193125-24-176312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312524176312/d863965d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-176312
- JSON: https://secwatch.observer/filing/0001193125-24-176312.json
- Plain text: https://secwatch.observer/filing/0001193125-24-176312.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.